Form 4: CEL-SCI Corp Director Watson Increases Stake with $27,800 Stock Purchase

Director Robert Eugene Watson purchased 20,000 shares of CEL-SCI Corp (CVM) at $1.39 per share on May 8, 2024, increasing his direct holdings.

Summary

• On May 8, 2024, Robert Eugene Watson, a director of CEL-SCI Corp (CVM), purchased 20,000 shares of common stock directly from the company.
• The purchase price was $1.39 per share, totaling $27,800.
• Following the transaction, Mr. Watson directly owns 24,431 shares of CEL-SCI Corp.

Sentiment

Score: 6

Explanation: A director purchasing shares is generally a positive sign, suggesting confidence in the company. However, the purchase is relatively small, so the impact is moderate.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored as they can provide insights into a company's performance and future expectations. A director's purchase is generally viewed more favorably than a sale.

Comparison to Industry Standards

• Comparing this transaction to other similar insider purchases in the biotech industry could provide context.
• For example, if other directors in peer companies like Amgen or Gilead Sciences have recently made similar purchases, it could indicate a broader positive sentiment in the sector.
• Conversely, if insider activity is primarily sales, it might suggest caution.

Stakeholder Impact

• The stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates